Aileron Therapeutics, Inc. Stock

Equities

ALRN

US00887A2042

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
3.77 USD -2.08% Intraday chart for Aileron Therapeutics, Inc. -1.31% +23.66%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 80.1M
Net income 2024 * -23M Net income 2025 * -27M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.04 x
P/E ratio 2025 *
-2.08 x
Employees 15
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.92%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Aileron Therapeutics, Inc.

1 day-2.08%
1 week-1.31%
Current month-17.14%
1 month-11.29%
3 months-19.62%
6 months+96.35%
Current year+23.66%
More quotes
1 week
3.65
Extreme 3.6501
4.00
1 month
3.28
Extreme 3.28
5.43
Current year
2.87
Extreme 2.87
7.42
1 year
1.01
Extreme 1.01
7.42
3 years
1.01
Extreme 1.01
28.00
5 years
1.01
Extreme 1.01
49.40
10 years
1.01
Extreme 1.01
309.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 23-10-30
Chief Tech/Sci/R&D Officer 51 07-10-31
Director/Board Member 53 14-08-31
Members of the board TitleAgeSince
Chairman 68 19-06-18
Director/Board Member 62 23-10-30
Chief Executive Officer 57 23-10-30
More insiders
Date Price Change Volume
24-05-17 3.77 -2.08% 19,489
24-05-16 3.85 -1.28% 57,080
24-05-15 3.9 0.00% 20,862
24-05-14 3.9 +0.52% 48,242
24-05-13 3.88 +1.57% 17,117

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.77 USD
Average target price
19 USD
Spread / Average Target
+403.98%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW